PMC:7172841 / 1861-2024 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T20","span":{"begin":18,"end":28},"obj":"Body_part"},{"id":"T21","span":{"begin":105,"end":118},"obj":"Body_part"}],"attributes":[{"id":"A20","pred":"fma_id","subj":"T20","obj":"http://purl.org/sig/ont/fma/fma63261"},{"id":"A21","pred":"fma_id","subj":"T21","obj":"http://purl.org/sig/ont/fma/fma264829"}],"text":"-19: the first is macrophage activation syndrome; the second is defective antigen-presentation driven by interleukin-6. An IL-6 blocker partially rescues immune dy"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T27","span":{"begin":18,"end":48},"obj":"Disease"}],"attributes":[{"id":"A27","pred":"mondo_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MONDO_0015545"}],"text":"-19: the first is macrophage activation syndrome; the second is defective antigen-presentation driven by interleukin-6. An IL-6 blocker partially rescues immune dy"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T18","span":{"begin":29,"end":39},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T19","span":{"begin":105,"end":118},"obj":"http://purl.obolibrary.org/obo/PR_000001393"}],"text":"-19: the first is macrophage activation syndrome; the second is defective antigen-presentation driven by interleukin-6. An IL-6 blocker partially rescues immune dy"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T15","span":{"begin":74,"end":81},"obj":"Chemical"},{"id":"T16","span":{"begin":123,"end":125},"obj":"Chemical"}],"attributes":[{"id":"A15","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"},{"id":"A16","pred":"chebi_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A17","pred":"chebi_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":"-19: the first is macrophage activation syndrome; the second is defective antigen-presentation driven by interleukin-6. An IL-6 blocker partially rescues immune dy"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T13","span":{"begin":18,"end":39},"obj":"http://purl.obolibrary.org/obo/GO_0042116"},{"id":"T14","span":{"begin":74,"end":94},"obj":"http://purl.obolibrary.org/obo/GO_0019882"}],"text":"-19: the first is macrophage activation syndrome; the second is defective antigen-presentation driven by interleukin-6. An IL-6 blocker partially rescues immune dy"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T76","span":{"begin":18,"end":28},"obj":"CL:0000235;GO:0042116"},{"id":"T77","span":{"begin":29,"end":39},"obj":"GO:0042116"},{"id":"T78","span":{"begin":74,"end":81},"obj":"CHEBI:59132;CHEBI:59132"},{"id":"T79","span":{"begin":105,"end":118},"obj":"PR:000001393"},{"id":"T80","span":{"begin":123,"end":127},"obj":"PR:000001393"},{"id":"T81","span":{"begin":154,"end":160},"obj":"UBERON:0002405;GO:0006955"}],"text":"-19: the first is macrophage activation syndrome; the second is defective antigen-presentation driven by interleukin-6. An IL-6 blocker partially rescues immune dy"}

{"project":"LitCovid-PubTator","denotations":[{"id":"95","span":{"begin":105,"end":118},"obj":"Gene"},{"id":"96","span":{"begin":123,"end":127},"obj":"Gene"},{"id":"101","span":{"begin":18,"end":48},"obj":"Disease"}],"attributes":[{"id":"A95","pred":"tao:has_database_id","subj":"95","obj":"Gene:3569"},{"id":"A96","pred":"tao:has_database_id","subj":"96","obj":"Gene:3569"},{"id":"A101","pred":"tao:has_database_id","subj":"101","obj":"MESH:D055501"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"-19: the first is macrophage activation syndrome; the second is defective antigen-presentation driven by interleukin-6. An IL-6 blocker partially rescues immune dy"}